<乌鸦传媒>Randomized Trial Backs HIF-2a Inhibition in Advanced RCC After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus Oct 24, 2023
<乌鸦传媒>More Data Support Adding Immunotherapy to Chemo in Advanced Endometrial Cancer PFS doubled and OS improved, driven by mismatch repair-deficient disease Oct 23, 2023
<乌鸦传媒>Antibody-Drug Conjugate Boosts Survival in Recurrent/Metastatic Cervical Cancer Tisotumab vedotin reduced risk of death by 30% compared with chemotherapy Oct 23, 2023
<乌鸦传媒>Targeting KRAS in NSCLC: Recent Progress and New Approaches Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available Oct 23, 2023 video
<乌鸦传媒>Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer Standard dose of sotorasib plus panitumumab reduced risk of progression by 51% vs standard care Oct 23, 2023
<乌鸦传媒>Is It a Sports Injury, or Something More Serious? Osteoscarcomas can present to any clinical setting, pediatric researcher says Oct 23, 2023
<乌鸦传媒>New First-Line Standard for Lung Cancers With EGFR Exon 20 Insertions Adding amivantamab to chemotherapy improved PFS, induced more rapid and durable responses Oct 23, 2023
<乌鸦传媒>'Practice-Changing' Data in Locally Advanced Cervical Cancer Strategies involving immunotherapy, induction chemo move the needle for first time in decades Oct 23, 2023
<乌鸦传媒>RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC Two randomized studies demonstrate significantly improved PFS against standard regimens Oct 22, 2023
<乌鸦传媒>Landmark Trial Produces New First-Line Standard for Advanced Bladder Cancer Enfortumab vedotin-pembrolizumab doubles OS, PFS versus chemotherapy Oct 22, 2023
<乌鸦传媒>Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation Oct 22, 2023
<乌鸦传媒>Suzanne Somers' Legacy Tainted by Celebrity Medical Misinformation The actress harnessed the power of traditional media like social media influencers do today Oct 22, 2023
<乌鸦传媒>Multi-Agent Treatment Offers Hope in Advanced or Recurrent Endometrial Cancer Durvalumab plus olaparib, or alone, paired with chemo boosts PFS in DUO-E trial Oct 21, 2023
<乌鸦传媒>Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years And early ctDNA reductions correlated with survival Oct 21, 2023
<乌鸦传媒>Carbohydrates and Long-Term Weight Change; Value of Cardiac Transfers Also in TTHealthWatch: reducing infections in joint replacement Oct 21, 2023 podcast
<乌鸦传媒>Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer But label update planned after potential harm observed in PD-L1-negative subgroup Oct 20, 2023
<乌鸦传媒>Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd Oct 19, 2023
<乌鸦传媒>Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatment News, features, and commentary about cancer-related issues Oct 19, 2023
<乌鸦传媒>Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A "Strategy will probably be practice-changing," says expert Oct 18, 2023
<乌鸦传媒>Senators Grill NIH Director Nominee on Drug Prices, Gender-Affirming Care Monica Bertagnolli, MD, makes her case during confirmation hearing Oct 18, 2023
<乌鸦传媒>Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train? It's time for clear guidelines Oct 18, 2023
<乌鸦传媒>What Caused the Pigmented Spot on Teen Boy's Eye? Authors discuss how best to diagnose and manage him, given the absence of any symptoms Oct 17, 2023
<乌鸦传媒>Pembrolizumab Wins FDA Approval in Operable Lung Cancer Checkpoint inhibitor demonstrated significant survival improvement in perioperative setting Oct 17, 2023
<乌鸦传媒>Hemoglobin Targets a Good Idea for Massively Transfused Patients Outcomes improved with values approaching 10 g/dL Oct 16, 2023
<乌鸦传媒>Suzanne Somers Dies; FDA Plans to Ban Hair Relaxers; Health Worker Minimum Wage Health news and commentary from around the Web gathered by 乌鸦传媒 staff Oct 16, 2023
<乌鸦传媒>Study Validates Accuracy of PREDICT Prognostication Tool in Breast Cancer Findings suggest it's a suitable decision aid for U.S. oncologists and patients Oct 13, 2023
<乌鸦传媒>Cryoprecipitate, REBOA Flop for Improving Major Hemorrhage Outcomes The first randomized trials of both approaches failed Oct 13, 2023
<乌鸦传媒>Hair Relaxers' Cancer Risk; Genetic Test Aids Rural Care; Drug Negotiation Fallout? News, features, and commentary about cancer-related issues Oct 13, 2023
<乌鸦传媒>New Lung Cancer Cases Are Higher in Younger Women vs Men And the higher incidence rates now extend to women ages 50 to 54 as well Oct 12, 2023
<乌鸦传媒>Combination Therapy Wins FDA Approval for BRAF-Mutated NSCLC Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients Oct 12, 2023
<乌鸦传媒>'Abortion Test' Sparks Concern; AI in Brain Surgery; 'Is There a Doctor on Board?' Health news and commentary from around the Web gathered by 乌鸦传媒 staff Oct 12, 2023
<乌鸦传媒>Rare Lung Bleeds Cluster in DOAC Users, Implications Unclear Pattern found in diffuse alveolar hemorrhage reports in FAERS Oct 11, 2023
<乌鸦传媒>Primary Care Intervention Improved Follow-Up of Abnormal Cancer Screening Results Follow-up testing within 120 days was improved with EHR reminders, patient outreach, navigation Oct 10, 2023
<乌鸦传媒>HER3-Targeted Drug Active in Advanced/Metastatic Breast Cancer Durable responses across all three major subtypes of breast cancer Oct 10, 2023
<乌鸦传媒>How a Multi-Cancer Screening Test Would Play Out in the Clinic True positives identified with Grail's assay typically confirmed in under 2 months Oct 10, 2023
<乌鸦传媒>Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Live News, features, and commentary about cancer-related issues Oct 06, 2023
<乌鸦传媒>Bladder-Sparing Neoadjuvant Protocol Gets High Marks for MIBC Complete clinical response predicted favorable outcomes for up to 2 years Oct 06, 2023
<乌鸦传媒>Sotorasib's Confirmatory Data in NSCLC Unreliable, Says FDA Panel But聽agency doesn't plan to immediately push for KRAS inhibitor's withdrawal Oct 05, 2023
<乌鸦传媒>Can ctDNA Guide Radiation Use in Oligometastatic NSCLC? Detectable circulating tumor DNA before radiotherapy linked with worse survival Oct 05, 2023
<乌鸦传媒>FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in Remission Large improvement in event-free survival, but questions linger about sources of data Oct 04, 2023
